Merck & Co.’s $11.5 billion bid for Acceleron Pharma is hitting a delay just as activist investors threaten to derail the deal altogether. Merck has …
It wasn’t long ago that Bristol Myers Squibb ran the numbers on potentially buying Acceleron Pharma, but that deal didn’t come together, and the biotech …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
